The 36-month beta value for MURA is at 5.37. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for MURA is 15.34M, and currently, shorts hold a 2.65% of that float. The average trading volume for MURA on April 01, 2025 was 254.85K shares.
MURA) stock’s latest price update
Mural Oncology plc (NASDAQ: MURA)’s stock price has gone rise by 6.78 in comparison to its previous close of 1.18, however, the company has experienced a -67.10% decrease in its stock price over the last five trading days. benzinga.com reported 2025-03-25 that On Tuesday, Mural Oncology plc MURA released data from the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck & Co Inc’s MRK Keytruda (pembrolizumab) vs. investigator choice single agent chemotherapy for platinum-resistant ovarian cancer.
MURA’s Market Performance
MURA’s stock has fallen by -67.10% in the past week, with a monthly drop of -65.76% and a quarterly drop of -60.38%. The volatility ratio for the week is 18.87% while the volatility levels for the last 30 days are 9.94% for Mural Oncology plc The simple moving average for the past 20 days is -60.24% for MURA’s stock, with a -63.56% simple moving average for the past 200 days.
Analysts’ Opinion of MURA
Many brokerage firms have already submitted their reports for MURA stocks, with Raymond James repeating the rating for MURA by listing it as a “Outperform.” The predicted price for MURA in the upcoming period, according to Raymond James is $18 based on the research report published on March 25, 2025 of the current year 2025.
Rodman & Renshaw gave a rating of “Buy” to MURA, setting the target price at $15 in the report published on June 28th of the previous year.
MURA Trading at -65.55% from the 50-Day Moving Average
After a stumble in the market that brought MURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.90% of loss for the given period.
Volatility was left at 9.94%, however, over the last 30 days, the volatility rate increased by 18.87%, as shares sank -63.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -65.85% lower at present.
During the last 5 trading sessions, MURA fell by -67.10%, which changed the moving average for the period of 200-days by -62.72% in comparison to the 20-day moving average, which settled at $3.1690. In addition, Mural Oncology plc saw -60.87% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MURA starting from Loew Caroline, who proposed sale 4,313 shares at the price of $3.36 back on Mar 04 ’25. After this action, Loew Caroline now owns shares of Mural Oncology plc, valued at $14,491 using the latest closing price.
Keson-Brookes Maiken, the of Mural Oncology plc, sale 1,469 shares at $3.45 during a trade that took place back on Mar 05 ’25, which means that Keson-Brookes Maiken is holding 73,564 shares at $5,068 based on the most recent closing price.
Stock Fundamentals for MURA
The total capital return value is set at -0.97. Equity return is now at value -63.57, with -54.55 for asset returns.
Based on Mural Oncology plc (MURA), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -16.02.
The liquidity ratio also appears to be rather interesting for investors as it stands at 5.83.
Conclusion
In conclusion, Mural Oncology plc (MURA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
